Aripiprazole

Nature Reviews Drug Discovery

Volumn 2, Issue 6, 2003, Pages 427-428

  Grady, Michelle A ^a   Gasperoni, Timothy L ^a   Kirkpatrick, Peter ^b  

^a Decision Resources Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; 7 [3 [4 (2,3 DIMETHYLPHENYL) 1 PIPERAZINYL]PROPOXY] 2(1H) QUINOLINONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; CHLORPROMAZINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; ILOPERIDONE; OLANZAPINE; OSANETANT; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 2 AGONIST; SEROTONIN 2 ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; ZIPRASIDONE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

BODY WEIGHT DISORDER; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; NOTE; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN; ANIMAL; CHEMISTRY; LEGAL ASPECT; PATENT; REVIEW; STATISTICS;

ANIMALS; CLINICAL TRIALS; HUMANS; PATENTS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 0038471047     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1114     Document Type: Note

References (9)

1. Lewis, D. A. & Lieberman, J. A. Catching up on schizophrenia: natural history and neurobiology. Neuron 28, 325-334(2000).
2. 2 receptor antagonist. Life Sci. 42, 1941-1954 (1988).
3. 2 receptor antagonistic activity J. Pharmacol. Exp. Ther. 274, 329-336 (1995).
4. Oshiro, Y. et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J. Med. Chem. 41, 658-667(1998).
5. 2 receptors. J. Pharmacol. Exp. Ther. 302, 381-389 (2002).
6. 1A receptor. Eur. J. Pharmacol. 441, 137-140 (2002).
7. FDA Drug Approvals List [online] (cited 28 April 2003) http://www.fda.gov/cder/foi/label/2002/21436_Ability_lbl.pdf (2002).
8. Kane, J. M. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63, 763-771(2002).
9. Taylor, D. M. Aripiprazole: a review of its pharmacology and clinical use. Int. J. Clin. Pract. 57, 49-54 (2003).